SBRA vs. TXG

In the year-to-date period, SBRA achieves a 2.01% return, which is significantly higher than TXG's -44.22% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Sabra Health Care REIT, Inc. (SBRA) and 10x Genomics, Inc. (TXG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current SBRA Sharpe Ratio is 1.48, which is higher than the TXG Sharpe Ratio of -1.03. The chart below compares the historical Sharpe Ratios of SBRA and TXG, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

SBRA's dividend yield for the trailing twelve months is around 6.92%, while TXG has not paid dividends to shareholders.

The maximum SBRA drawdown since its inception was -74.93%, smaller than the maximum TXG drawdown of -96.47%. Use the drawdown chart below to compare losses from any high point for SBRA and TXG. For additional features, visit the drawdowns tool.

The current volatility for Sabra Health Care REIT, Inc. (SBRA) is 8.22%, while 10x Genomics, Inc. (TXG) has a volatility of 30.05%. This indicates that SBRA experiences smaller price fluctuations and is considered to be less risky than TXG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Sabra Health Care REIT, Inc. and 10x Genomics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.